Dapirolizumab pegol (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dapirolizumab pegol" in English language version.

refsWebsite

Global rank English rank

2^nd place

4^th place

11^th place

8^th place

5^th place

1,226^th place

1,421^st place

bmj.com

Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data". Annals of the Rheumatic Diseases. 82 (Suppl 1): 272–273. doi:10.1136/annrheumdis-2023-eular.1991. ISSN 0003-4967. S2CID 259786801.
Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804. PMID 33956056.

Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804. PMID 33956056.

Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804. PMID 33956056.

Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data". Annals of the Rheumatic Diseases. 82 (Suppl 1): 272–273. doi:10.1136/annrheumdis-2023-eular.1991. ISSN 0003-4967. S2CID 259786801.